Who We Are
What We Do
Corporate Responsibility
Patients and HCPS
Contact us
Careers | Investors | Patients and HCPS | Contact us
Careers Investors Patients and HCPS Contact us
Home / Company News / Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart in Kazakhstan
Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart in Kazakhstan

Beijing, China, August 24, 2022 —  Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087. SH) is pleased to announce its insulin aspart product has been approved by the Ministry of Health of the Republic of Kazakhstan for the treatment of diabetes.


The approval is another significant result achieved in Kazakhstan following the approval of insulin glargine. Moreover, this is the first marketing authorization Gan & Lee has received from an overseas regulatory authority, marking an important breakthrough in the company’s globalization.


Kazakhstan is located in central Asia, bordering China, with a population of 19.12 million (as of January 2022)1 and a GDP per capita of $10,041.5 (2021, international exchange rates)2. According to the International Diabetes Federation (IDF) Atlas 10th edition, as of 2021, about 0.8 million adults (aged 20 to 79) in Kazakhstan are living with diabetes with a prevalence of 6.8%3.


Kazakhstan is a public market dominated by government tenders. There is only one insulin aspart product - NovoRapid® available on the market at the moment. As the second approved insulin aspart manufacturer, Gan & Lee's insulin aspart product offers another treatment option for patients with diabetes in Kazakhstan.


Insulin aspart is a rapid-acting insulin analog that can be absorbed quickly right after injection before or after meals. Compared with soluble human insulin, Insulin aspart has a faster onset and a shorter duration of action after subcutaneous injection. In addition, it can mimic the human body’s physiological insulin secretion patterns after meals, helping to improve postprandial blood glucose significantly.


“I am very please to witness Gan and Lee's overseas marketing authorization in Kazakhstaan. This is an important acheivement for our international strategy Moving forward, we expect to see more products going global through the Gan & Lee brand.” said Jason Wu, senior director of the international business affairs department of Gan & Lee.



1. Kazakhstan Country Profilehttps://www.fmprc.gov.cn/web/gjhdq_676201/gj_676203/yz_676205/1206_676500/1206x0_67650/

2. Kazakhstan | Data. (2022). Retrieved 24 August 2022, from https://data.worldbank.org.cn/country/kazakhstan?view=chart 

3. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).


In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 


Copyright © 2021 Gan & Lee Pharmaceuticals Co Ltd . All Rights Reserved.
Our websites


I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.